PharmAsia News Business Bulletin
This article was originally published in Scrip
A new regular roundup of commercial stories appearing in Scrip's sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace.
You may also be interested in...
India's largest biopharmaceutical company, Biocon, on May 17 sought to quell any confusion over its oral insulin program, underscoring that it stays confident of the molecule's prospects and is committed to taking it to the next stage of clinical development after the exit of partner Bristol-Myers Squibb (BMS).
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
While it was not as affected as some other countries, Japan still had the pandemic to deal with and regulators responded while managing to keep up regular product review work, including several world-first approvals. Coronavirus vaccine roll-outs and the first general annual reimbursement price cut are on the cards for this year.